Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recen...
主要な著者: | Smith, C, Mirza, F, Pasquetto, V, Tscharke, D, Palmowski, M, Dunbar, P, Sette, A, Harris, A, Cerundolo, V |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2005
|
類似資料
-
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
著者:: Smith, C, 等
出版事項: (2005) -
Immunodomination during peripheral vaccinia virus infection.
著者:: Leon C W Lin, 等
出版事項: (2013-01-01) -
Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
著者:: Sharpe, S, 等
出版事項: (2003) -
Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.
著者:: Gileadi, U, 等
出版事項: (1999) -
Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
著者:: Caroline Staib, 等
出版事項: (2003-04-01)